Iterum Therapeutics plc (ITRMF) Change in Accured Expenses (2017 - 2025)

Iterum Therapeutics' Change in Accured Expenses history runs 9 years deep, the most recent figure standing at -$520000.0 for Q2 2025.

• In Q2 2025, Change in Accured Expenses fell 229.68% year-over-year to -$520000.0; the TTM figure through Sep 2025 stood at $3.3 million (up 135.28% YoY), while the FY2024 annual figure was -$385000.0, down 8.76% from the prior year.
• Change in Accured Expenses for Q2 2025 stood at -$520000.0, down from -$48000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.0 million in Q3 2023, with the low at -$5.9 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is -$102000.0 (2023), against an average of $67555.6.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 619.05% in 2022, then slumped 5686.27% in 2024.
• Iterum Therapeutics' Change in Accured Expenses stood at -$525000.0 in 2021, then jumped by 215.81% to $608000.0 in 2022, then plunged by 944.08% to -$5.1 million in 2023, then surged by 175.7% to $3.9 million in 2024, then plunged by 113.38% to -$520000.0 in 2025.
• Business Quant data shows ITRMF's Change in Accured Expenses at -$520000.0 in Q2 2025, -$48000.0 in Q1 2025, and $3.9 million in Q4 2024.